Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fasting for long COVID: small study tests if going without food for a week is safe and helpful.

NCT ID NCT07418567

Symptom relief Sponsor: Université de Sherbrooke Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small study tested whether a 7-day fast is a safe and acceptable option for adults with Long COVID. 25 participants fasted at home and had checkups before and after. The goal was to see if fasting could improve daily function and quality of life by reducing inflammation. Results will show if this approach is worth studying further.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

May 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-64 years * Diagnosis Long Covid based on WHO criteria (post-acute COVID-19 symptoms persisting ≥12 weeks) and validiated by an experienced cinician * Normal body Mass Index (18.5 to 39 kg/m2) * Able to communicate in and comprehend English and/or French language * Present written / signed declaration of consent * Ability to understand the patient information and willingness to sign the consent form * Willing to limit physical activity during prolonged fasting Exclusion Criteria: * Current underweight condition (body mass index less than 18.5 kg/m2) or weight loss exceeding 3 kg within the last month or 5 kg within the last three months. * Current or history of eating disorder (e.g., anorexia, bulimia). * Psychiatric condition that limits understanding of the examination protocol (unable to consent) * Participation in another intervention study. * Fasting during the last six months * Pregnancy or breastfeeding status. * Diagnosis of chronic inflammatory bowel diseases, celiac disease or colorectal cancer according to the guidelines of the Canadian Society of Gastroenterology * Use of anti-psychotic drugs * Start of novel drug therapy for long COVID * Contraindication for additional blood draws (e.g. hemoglobin \<100) * Taking opioid analgesics or undergoing treatment for opioid addiction * Opioid dependence or withdrawal syndrome * Type 1 or 2 Diabetes, or history of hypoglycemia * Active cancer * Baseline E+ (Na, K, Mg, phosphate) within normal range * Baseline ALT \< 60 * Baseline Hb \> 100 * Baseline INR within normal range * Baseline DFG \< 50

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fasting long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID syndrome

Contacts and locations

Locations

  • Centre de recherche du CIUSSSE-CHUS

    Sherbrooke, Quebec, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.